Unknown

Dataset Information

0

Crystallization and preliminary diffraction studies of GIM-1, a class B carbapenem-hydrolyzing ?-lactamase.


ABSTRACT: GIM-1 is a member of the class B carbapenemases (metallo-?-lactamases; MBLs) and has a wide spectrum of activity against carbapenems, penicillins and extended-spectrum cephalosporins, but not aztreonam. GIM-1 presents an enormous challenge to infection control, particularly in the eradication of Gram-negative pathogens including Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii and nonfermenters. There are presently few or no drugs in late-stage development for these pathogens and GIM-1 is a potential target for the development of antimicrobial agents against pathogens producing MBLs. In this study, GIM-1 was cloned, overexpressed and crystallized. The GIM-1 crystals diffracted to 1.4?Å resolution and belonged to the orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a = 38.5, b = 67.6, c = 72.8?Å. One molecule is present in the asymmetric unit, with a corresponding V(M) of 1.69?Å(3)?Da(-1) and a solvent content of 27.1%.

SUBMITTER: Hong MK 

PROVIDER: S-EPMC3497985 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Crystallization and preliminary diffraction studies of GIM-1, a class B carbapenem-hydrolyzing β-lactamase.

Hong Myoung-Ki MK   Lee Jung Hun JH   Kwon Dae Beom DB   Kim Jin-Kwang JK   Tran Thi-Huyen TH   Nguyen Dinh-Duc DD   Jeong Byeong Chul BC   Lee Sang Hee SH   Kang Lin-Woo LW  

Acta crystallographica. Section F, Structural biology and crystallization communications 20120928 Pt 10


GIM-1 is a member of the class B carbapenemases (metallo-β-lactamases; MBLs) and has a wide spectrum of activity against carbapenems, penicillins and extended-spectrum cephalosporins, but not aztreonam. GIM-1 presents an enormous challenge to infection control, particularly in the eradication of Gram-negative pathogens including Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii and nonfermenters. There are presently few or no drugs in late-stage development for these pathogens  ...[more]

Similar Datasets

| S-EPMC3186976 | biostudies-literature
| S-EPMC2786334 | biostudies-literature
| S-EPMC3186949 | biostudies-literature
| S-EPMC2981293 | biostudies-literature
| S-EPMC3535949 | biostudies-literature
| S-EPMC163477 | biostudies-other
| S-EPMC3199476 | biostudies-literature
| S-EPMC2496857 | biostudies-literature
| S-EPMC3215043 | biostudies-literature
| S-EPMC3993228 | biostudies-literature